Vancomycin Dose Calculator — Loading, Maintenance & AUC-Guided

How to Use This Calculator

1. Enter actual body weight, CrCl (from Cockcroft-Gault), and select dosing method.
2. Loading dose, maintenance dose, interval, and monitoring target appear instantly.
3. Use the Loading Dose tab for severity-adjusted loading and infusion time guidance.
4. Use the AUC-Guided tab to interpret current AUC and calculate dose adjustment.
5. Use the Professional tier for obesity, indication-specific targets, and monitoring notes.

Formula

Example

Frequently Asked Questions

• How is vancomycin dosed? ▼
  Vancomycin is a glycopeptide antibiotic used primarily for gram-positive infections, particularly MRSA. Dosing uses actual body weight for non-obese patients and adjusted body weight (IBW + 0.4 × [ABW − IBW]) for obese patients (BMI > 30 or weight > 130% of IBW). The loading dose is 25–30 mg/kg (rounded to nearest 250 mg) given once to rapidly achieve therapeutic concentrations. Maintenance doses of 15–20 mg/kg (typically 15–20 mg/kg per dose) are given every 8–12 hours for normal renal function, extending to every 24 hours for moderate renal impairment (CrCl 30–50 mL/min) and every 48–72 hours for severe impairment (CrCl < 30 mL/min). Haemodialysis patients require supplemental dosing after each session. The infusion rate should not exceed 10–15 mg/min to prevent infusion-related reactions (Red Man Syndrome). Since the 2020 ASHP/IDSA/SIDP joint guideline, AUC-guided monitoring has replaced trough-only monitoring as the preferred approach due to superior safety and equivalent efficacy.
• What is AUC-guided vancomycin dosing and why is it preferred over trough monitoring? ▼
  AUC-guided vancomycin monitoring targets the area under the 24-hour concentration-time curve (AUC₂₄) divided by the minimum inhibitory concentration (MIC) of the causative organism. The target AUC₂₄/MIC is 400–600 mg·h/L (assuming MIC of 1 mg/L for MRSA). The 2020 joint ASHP/IDSA/SIDP vancomycin monitoring guideline formally recommended AUC-guided dosing over trough-only monitoring based on evidence that: (1) trough-only monitoring systematically overdoses patients — clinicians targeting troughs of 15–20 mg/L frequently produce AUC values > 600 mg·h/L, which is independently associated with nephrotoxicity; (2) AUC-guided dosing achieves equivalent clinical cure rates while significantly reducing rates of vancomycin-induced nephrotoxicity (approximately 50% reduction in comparative studies); and (3) the relationship between efficacy and AUC/MIC is better validated pharmacodynamically than trough alone. AUC is best estimated using Bayesian pharmacokinetic software (e.g., DoseMe, Tucuxi, InsightRx) from at least two serum vancomycin concentrations drawn at known times after a dose.
• What trough target is appropriate for vancomycin if trough monitoring is used? ▼
  Although AUC-guided monitoring is now the preferred method, trough-only monitoring remains in use at many institutions without Bayesian dosing software. When using legacy trough-based monitoring, the targets are: trough 10–15 mg/L for uncomplicated skin and soft tissue infections or urinary tract infections; trough 15–20 mg/L for serious deep-seated infections including MRSA bacteremia, endocarditis, osteomyelitis, and hospital-acquired pneumonia. The 2020 guideline explicitly discourages targeting troughs > 20 mg/L as a surrogate for AUC, as this strategy has high nephrotoxicity rates without proven efficacy benefit. Troughs should be measured at steady state — generally 30 minutes before the fourth or fifth dose. A trough drawn too early (before steady state) will underestimate the true steady-state concentration and may lead to unnecessary dose escalation. If AUC can be estimated from two-level sampling (one peak approximately 1–2 hours post-infusion and one trough), this is preferred even in the absence of formal Bayesian software.
• Why is vancomycin nephrotoxic and how is it monitored? ▼
  Vancomycin-associated nephrotoxicity (VAN) is defined as a ≥ 0.5 mg/dL or ≥ 50% increase in serum creatinine from baseline on two consecutive readings, in the absence of another explanation. The mechanism involves direct proximal tubular toxicity — vancomycin accumulates in renal tubular cells via megalin-mediated endocytosis, generating reactive oxygen species and causing oxidative tubular damage. Risk factors for VAN include: supratherapeutic AUC (> 600 mg·h/L); concurrent nephrotoxin use (aminoglycosides, NSAIDs, IV contrast, piperacillin-tazobactam — the latter combination is particularly implicated and should be avoided when alternatives exist); prolonged treatment duration (> 7 days); baseline renal impairment; critically ill status with haemodynamic instability; and obesity. Monitoring requires serum creatinine at least every 48–72 hours during treatment, daily in high-risk patients. If VAN develops, the dose or frequency should be reduced and AUC reassessed. Discontinuation is warranted if creatinine continues to rise significantly or if alternative agents (daptomycin, linezolid, ceftaroline) are appropriate for the indication.
• How is vancomycin dosed in obesity? ▼
  Obesity significantly complicates vancomycin pharmacokinetics. Vancomycin is distributed primarily in body water, and obese patients have an expanded volume of distribution that increases linearly with total body weight. Both volume of distribution and clearance are increased in obesity, meaning doses based on ideal body weight will be systematically subtherapeutic. The 2020 ASHP/IDSA guidelines recommend using actual body weight for both loading and maintenance doses in obese patients, but note that AUC monitoring is especially important in this population because the relationship between dose and exposure varies considerably between individuals. An alternative strategy for very obese patients (BMI > 40 or weight > 200% of IBW) is to use adjusted body weight (IBW + 0.4 × [ABW − IBW]) as a starting point, with early Bayesian-guided AUC assessment after the first two doses to personalise the regimen. Obese patients are also at higher baseline risk for VAN, so renal function monitoring should be more frequent. Maximum individual dose recommendations of 3000–3500 mg per dose are sometimes cited to limit infusion reactions, though these limits should not prevent adequate dosing when AUC monitoring confirms subtherapeutic exposure.

Related Calculators